The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Down syndrome and Alzheimer's disease: Common pathways, common goals
Open accessAbstract
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease‐modifying treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with Down syndrome (DS), caused by trisomy of chromosome 21 (chr21, T21), are strongly predisposed to Alzheimer’s disease (AD), due to triplication of the APP gene, with ∼100% penetrance of AD brain pathology by age 40 and variable onset of dementia thereafter.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hyperactivation of the S6K proteins correlates with increased Tau pathology and dysregulation of the insulin/IGF/mTOR signaling pathway, both in individuals with DS‐AD 55 and in idiopathic AD. 56”
From Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations (2026) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED AND REPLACED: Nerve growth factor metabolic dysfunction in Down’s syndrome brains
Iulita, M. F., Carmo, S. D., Ower, A. K., Fortress, A. M., Aguilar, L. F., Hanna, M., Wısnıewskı, T., Granholm, A., Buhusi, M. C., Busciglio, J. A., et al. (2014) · Brain · doi:10.1093/brain/awt372 · Cited by 94
Self-citationRetractedInhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776
Self-citationAmyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 656
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584
Self-citationA Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561
Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543
Self-citationCognitive deficits and associated neurological complications in individuals with Down's syndrome
Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484
Self-citationMolecular mapping of alzheimer‐type dementia in Down's syndrome
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C., & Butler, A. C. (1998) · Annals of Neurology · doi:10.1002/ana.410430316 · Cited by 414
The pathological association between down syndrome and Alzheimer disease
Mann, D. M. A. (1988) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(88)90041-3 · Cited by 346
Domains of genome-wide gene expression dysregulation in Down’s syndrome
Letourneau, A., Santoni, F. A., Bonilla, X., Sailani, M. R., Gonzalez, D., Kind, J., Chevalier, C., Thurman, R., Sandstrom, R. S., Hibaoui, Y., et al. (2014) · Nature · doi:10.1038/nature13200 · Cited by 319
Jiang, Y., Mullaney, K. A., Peterhoff, C. M., Che, S., Schmidt, S. D., Boyer‐Boiteau, A., Ginsberg, S. D., Cataldo, A. M., Mathews, P. M., & Nixon, R. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908953107 · Cited by 293
Self-citationAlzheimer's disease in Down syndrome: Neurobiology and risk
Zigman, W. B., & Lott, I. T. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20163 · Cited by 290
Self-citationOverexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome
Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272
Self-citationParallels of craniofacial maldevelopment in down syndrome and Ts65Dn mice
Richtsmeier, J. T., Baxter, L. L., & Reeves, R. H. (2000) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(200002)217:2 · Cited by 260
Self-citationA mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions
Yu, T., Li, Z., Jia, Z., Clapcote, S. J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq179 · Cited by 248
Ginsberg, S. D., Alldred, M. J., Counts, S. E., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.030 · Cited by 243
Self-citationHof, P. R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280065020 · Cited by 242
Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 238
Granholm, A., Sanders, L., & Crnic, L. S. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7289 · Cited by 237
Self-citationTrillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M. M., Miguel, Z. D., Ashford, J. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.008 · Cited by 230
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Wilcock, D. M., & Griffin, W. S. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-84 · Cited by 230
Neurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225 · cited 2×
“Also, linking cognitive studies and functional imaging may allow prediction of cognitive impairment and provide a platform for early intervention [66].”
BackgroundSelf-citationBelichenko, P. V., Kleschevnikov, A. M., Salehi, A., Epstein, C. J., & Mobley, W. C. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21433 · Cited by 208
Self-citationOligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism
Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B. J., Zhang, H., Moore, A. Z., Staniszewski, A., Arancio, O., Kim, T.-W., & Di Paolo, G. (2008) · Nature Neuroscience · doi:10.1038/nn.2100 · Cited by 199
Development and validation of the Arizona Cognitive Test Battery for Down syndrome
Edgin, J. O., Mason, G. M., Allman, M. J., Capone, G. T., DeLeon, I. G., Maslen, C. L., Reeves, R. H., Sherman, S. L., & Nadel, L. (2010) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-010-9054-3 · Cited by 194
Self-citationSelective Cell Death of Hyperploid Neurons in Alzheimer’s Disease
Arendt, T., Brückner, M. K., Mosch, B., & Lösche, A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090955 · Cited by 193
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome
Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190
Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., Pooter, T. D., van Duijn, C. M., Deyn, P. P. D., & Broeckhoven, C. V. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 188
Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187
Self-citationMolecular characterization of the translocation breakpoints in the down syndrome mouse model Ts65Dn
Reinholdt, L. G., Ding, Y., Gilbert, G. T., Czechanski, A., Solzak, J. P., Roper, R. J., Johnson, M. T., Donahue, L. R., Lutz, C., & Davisson, M. T. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9357-z · Cited by 186
Voronov, S. V., Frere, S. G., Giovedi, S., Pollina, E. A., Borel, C., Zhang, H., Schmidt, C., Akeson, E. C., Wenk, M. R., Cimasoni, L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803756105 · Cited by 174
Self-citationMouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166
Down syndrome and Alzheimer's disease: A link between development and aging
Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 161
Self-citationChromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease
Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 147
Self-citationNeuropathological Changes in Down's Syndrome Hippocampal Formation
Hyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 147
Down Syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD)
Ekstein, S., Glick, B., Weill, M., Kay, B., & Berger, I. (2011) · Journal of Child Neurology · doi:10.1177/0883073811405201 · Cited by 137
Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 135
Self-citationImaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
Handen, B. L., Cohen, A. D., Umapathy, C., Bulova, P. D., Cannon, S. A., Cohen, W. I., Mathis, C. A., Price, J. C., & Klunk, W. E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.229 · Cited by 134
Life-long overexpression of S100β in Down’s syndrome: implications for Alzheimer pathogenesis
Griffin, W. S. T., Sheng, J. G., McKenzie, J. E., Royston, M. C., Gentleman, S., Brumback, R. A., Cork, L. C., Bigio, M. R. D., Roberts, G. W., & Mrak, R. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00074-8 · Cited by 134
Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer’s Disease
Teipel, S. J., & Hampel, H. J. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9047-x · Cited by 134
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Self-citationMinocycline prevents cholinergic loss in a mouse model of Down's syndrome
Hunter, C. L., Bachman, D., & Granholm, A. (2004) · Annals of Neurology · doi:10.1002/ana.20250 · Cited by 123
Self-citationAptamers and the RNA World, Past and PresentPreprint
Gold, L., Janjić, N., Jarvis, T. C., Schneider, D., Walker, J. J., Wilcox, S. K., & Zichi, D. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003582 · Cited by 119
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions
Sturgeon, X., & Gardiner, K. J. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9321-y · Cited by 117 · cited 1×
“Of the several DSmouse models that have been generated, the most widely used is the Ts65Dn model for studying DS, which is trisomic for 88 of 161 of the ortholog protein coding genes on human chromosome 21 [51].”
MethodSelf-citationAltered DNA Methylation in Leukocytes with Trisomy 21
Kerkel, K., Schupf, N., Hatta, K., Pang, D. I., Salas, M. C., Kratz, A. F., Minden, M. D., Murty, V. V. V. S., Zigman, W. B., Mayeux, R. P., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001212 · Cited by 114
Self-citationMolecular basis of pharmacotherapies for cognition in Down syndrome
Gardiner, K. (2009) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.10.010 · Cited by 113
Self-citationChapter 4 Alzheimer's Disease in Adults with Down Syndrome
Zigman, W. B., Devenny, D. A., Krinsky‐McHale, S. J., Jenkins, E. C., Urv, T. K., Węgiel, J., Schupf, N., & Silverman, W. P. (2008) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)00004-9 · Cited by 106
Self-citationCossec, J., Lavaur, J., Berman, D. E., Rivals, I., Hoischen, A., Stora, S., Ripoll, C., Mircher, C., Grattau, Y., Olivo‐Marín, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds142 · Cited by 106
Worldwide Alzheimer's Disease Neuroimaging Initiative
Carrillo, M. C., Bain, L. J., Frisoni, G. B., & Weiner, M. W. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.04.007 · Cited by 104
Self-citationNeuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease
Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104
DYRK1A: a potential drug target for multiple down syndrome neuropathologies
Becker, W., Soppa, U., & Tejedor, F. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660186 · Cited by 103
Head, E., Silverman, W. P., Patterson, D. W., & Lott, I. T. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/412536 · Cited by 100
Self-citationRegulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A
Wu, Q., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 100
Self-citationWęgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98
Self-citationRoyston, M. C., Mann, D. M. A., Pickering-Brown, S. M., Owen, F., Perry, R., Raghavan, R., Khin-IMu, C., Tyrer, S. P., Day, K. A., Crook, R., et al. (1994) · Neuroreport · doi:10.1097/00001756-199412000-00044 · Cited by 94
Onset of dementia is associated with apolipoprotein E ε4 in Down's syndrome
Schupf, N., Lee, J. H., Kapell, D., Zigman, W. B., Canto, B., Tycko, B., & Mayeux, R. P. (1996) · Annals of Neurology · doi:10.1002/ana.410400518 · Cited by 91
Self-citationPrasher, V. P., Sajith, S. G., Rees, S. D., Patel, A., Tewari, S., Schupf, N., & Zigman, W. B. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2039 · Cited by 89
Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade
Potter, H., & Wısnıewskı, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/489428 · Cited by 84
Self-citationChange in plasma Aβ peptides and onset of dementia in adults with Down syndrome
Schupf, N., Zigman, W. B., Tang, M. X., Pang, D. I., Mayeux, R. P., Mehta, P. D., & Silverman, W. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 81
Self-citationThe proteins of human chromosome 21
Gardiner, K., & Costa, A. C. S. (2006) · American Journal of Medical Genetics. Part C, Seminars in Medical Genetics · doi:10.1002/ajmg.c.30098 · Cited by 74
Self-citationPositron Emission Tomography of Brain β-Amyloid and Tau Levels in Adults With Down Syndrome
Nelson, L. D., Siddarth, P., Kepe, V., Scheibel, K. E., Huang, S. C., Barrio, J. R., & Small, G. W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.104 · Cited by 72
Age-Related Neurodegeneration and Memory Loss in Down Syndrome
Lockrow, J. P., Fortress, A. M., & Granholm, A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/463909 · Cited by 68
Self-citationLandt, J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.36 · Cited by 65
Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors
Borysov, S. I., Granic, A., Padmanabhan, J., Walczak, C., & Potter, H. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15478 · Cited by 63
Self-citationLoss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age
Mann, D. M. A., Yates, P. O., Marcyniuk, B., & Ravindra, C. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90223-1 · Cited by 61
Sabbagh, M. N. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.535 · Cited by 52
Self-citationPathways to cognitive deficits in Down syndrome
Sturgeon, X., Le, T., Ahmed, M. M., & Gardiner, K. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00005-4 · Cited by 52
Self-citationDown's syndrome and Alzheimer's disease: towards secondary prevention
Ness, S. L., Rafii, M. S., Aisen, P. S. S., Krams, M., Silverman, W. P., & Manji, H. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3822 · Cited by 51
Self-citationDementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population
Mullins, D., Daly, E., Simmons, A., Beacher, F. D. C. C., Foy, C. M. L., Lovestone, S., Hallahan, B. P., Murphy, K. C., & Murphy, D. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-19 · Cited by 50
A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model
Lockrow, J. P., Boger, H. A., Gerhardt, G. A., Aston‐Jones, G., Bachman, D., & Granholm, A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101218 · Cited by 49
Self-citationLv, H., Jia, L., & Jia, J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.001 · Cited by 43
Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain
Ahmed, M. M., Dhanasekaran, A. R., Tong, S., Wiseman, F. K., Fisher, E., Tybulewicz, V. L. J., & Gardiner, K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt017 · Cited by 43
Self-citationKleschevnikov, A. M., Belichenko, P. V., Salehi, A., & Wu, C. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00010-8 · Cited by 30
Blanchard, J., Bolognin, S., Chohan, M. O., Rabe, A., Iqbal, K., & Grundke, I. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318236e9ad · Cited by 28
Self-citationJenkins, E. C., Ye, L., Velinov, M. T., Krinsky‐McHale, S. J., Zigman, W. B., Schupf, N., & Silverman, W. P. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32066 · Cited by 23
Self-citation
Cited by
Sorted by citations
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
López, J. A., González, H. M., & Léger, G. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 887
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 325
Metadata
- Authors
- Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., Lott, I., Mobley, W., Ness, S., Nixon, R., Potter, H., Reeves, R., Sabbagh, M., Silverman, W., Tycko, B., Whitten, M., & Wisniewski, T.
- Affiliations
- Alzheimer's Association (US)
- University of Colorado Boulder (US)
- Medical and Scientific Relations Alzheimer's Association Chicago IL USA
- Department of Pathology and Cell Biology Columbia University Medical Center and The Taub Institute for Research on Alzheimer's Disease and The Aging Brain New York NY USA
- Trinitas Regional Medical Center (US)
- University of Colorado Anschutz (US)
- Medical University of South Carolina (US)
- Department of Neurochemistry New York State Institute for Basic Research in Developmental Disabilities New York NY USA
- Janssen Research & Development (United States) (US)
- Brigham and Women's Hospital (US)
- University of California, Irvine (US)
- University of California San Diego (US)
- NYU Langone Health (US)
- Johns Hopkins University (US)
- Banner Health (US)
- Kennedy Krieger Institute (US)
- Columbia University Irving Medical Center (US)
- Global Down Syndrome Foundation (US)
- Department of Neurology, Pathology, and Psychiatry New York University, Langone Medical Center New York NY USA
- Corresponding author
- Hartley, Dean
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-12-12
- Volume
- 11
- Issue
- 6
- Pages
- 700-709
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC4817997
- OpenAlex
- W1991023630
- Cited by
- 290
- References
- 80
- Citations by year
- 2026: 12 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 46 · 2020: 27 · 2019: 26 · 2018: 15 · 2017: 19 · 2016: 20 · 2015: 13 · 2014: 2
- FWCI
- 17.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Aging (R01AG012122, R01AG037942)
- National Institute of Neurological Disorders and Stroke (R01NS076291)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Clinical Trials as Topic, Congresses as Topic, Disease Models, Animal, Down Syndrome, Humans, Neuropsychological Tests, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
